Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion (FOV2302)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00969293|
Recruitment Status : Terminated
First Posted : September 1, 2009
Last Update Posted : January 10, 2012
|Condition or disease||Intervention/treatment||Phase|
|Macular Edema Central Retinal Vein Occlusion||Drug: FOV2302 (Ecallantide)||Phase 1|
Occlusive retinal vascular disease is not uncommon. Central retinal vein occlusion (CRVO) is the second most common vision-impairing vascular disorder of the retina following diabetic retinopathy. Severe visual loss from CRVO is caused by a combination of retinal edema and neovascular proliferation and ischemia. Vascular endothelial factors as they stimulate angiogenesis and increase vascular permeability, are majors pathogenic factors in CRVO. Counteracting these neovascular effects provide significant therapeutic benefit to subjects suffering from this disorder. Macular edema in this condition results from a conjunction of several, as yet, partially unknown factors.
Macular edema may occur in diseases causing cumulative injury over many years, such as diabetic retinopathy, or as a result of more acute events, such as branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Dose Escalating Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion|
|Study Start Date :||September 2009|
|Primary Completion Date :||July 2011|
|Estimated Study Completion Date :||March 2012|
Drug: FOV2302 (Ecallantide)
Single intravitreal injection into the relevant eye.
Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.
Duration of Treatment: Single injection with 3 months follow-up.
- Safety and tolerability parameters to determine MTD: 1. Systemic parameters: adverse events (AEs), coagulation parameters (APTT, ACT) 2. Ophthalmologic parameters: BCVA, OCT, ocular inflammation, IOP [ Time Frame: 3 months post-dose ]
- Assess the pharmacodynamics up to five dose levels of a single administration of FOV2302 (ecallantide) by longitudinal measurements of the percent change of the macula thickness versus baseline as measured by OCT [ Time Frame: 3 months post-dose ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00969293
|CHU d'Amiens, Centre Saint-Victor|
|Amiens, France, 80054|
|Centre Intercommunal de Creteil|
|Creteil, France, 94010|
|CHU de Dijon, Hôpital Général|
|Dijon, France, 21000|
|Marseille, France, 13008|
|CHU de Nantes|
|Nantes, France, 44093|
|Centre Hospitalier National d'Ophthalmologies des XV-XX|
|Paris, France, 75012|
|Paris, France, 75015|
|Paris, France, 75571|
|Study Chair:||Alain Gaudric, MD||Hopital Lariboisiere|